Next-Generation PSMA-Targeted ⁶⁴Cu Terpyridine Theranostic: From Enhanced Tumor Targeting to In Vivo Efficacy in Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EPS-156; Pres time: Oct 19, 2026; 04:45 PM - 06:15 PM; Location: Hall G2; "Overall, these findings validate the ⁶⁴Cu-terpyridine PSMA conjugate as a promising theranostic candidate, combining efficient tumor targeting, robust in vivo therapeutic efficacy, and advantageous dosimetry, thereby warranting clinical investigation for PCa theranostics"
Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
H. Talebian 1; S. Ait-Mohand 1; É. Rousseau 2; P. Mercy Ignatius Arokia Doss 1; L. Sanche 1; B. Guérin 1
|